argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year Run

argenx has delivered powerful long term gains, and the latest jump on fresh clinical data has put an even brighter spotlight on whether the current share price is adequately supported by its earnings. With the stock now back in focus after recent trial updates and sales headlines, the key issue for you is how much of that story is already embedded in the earnings multiple.

• argenx has produced a 202.1% return over the past 5 years, which puts a lot of past success on the table when judging what its current earnings are worth.

• Positive study results around VYVGART Hytrulo and strong recent Vyvgart sales may support expectations for future profitability, which matters directly for how richly investors are willing to value today's earnings stream.

• The analysts covering argenx have run their own numbers. See what analysts think argenx's shares could be worth .

The issue now is whether argenx's current share price, after that multi year run and recent news driven moves, is justified by the earnings it is generating today.

If you want a clearer yardstick for this type of earnings-driven biotech story, it may be useful to compare argenx with 124 healthcare AI stocks .

Is argenx Getting Expensive on Earnings?

P/E is the cleanest way to think about argenx right now because earnings have turned into a more meaningful anchor for the story. On that yardstick, argenx trades on roughly 29.2x, which is above both the wider biotech sector average of about 24.4x and the peer group near 39.0x. The stock therefore prices in a richer earnings tag than the typical biotech, while still sitting below the more aggressively valued peers in its specialist group.

Because the fair P/E for argenx, based on its own growth profile, margins, size and risk, screens lower than the current 29.2x, the shares come across as overvalued on this framework. The recent jump after positive ALKIVIA Phase 3 data has reinforced confidence around VYVGART Hytrulo, yet the P/E already asks investors to pay a premium versus what this model would suggest for today's earnings power. Explore the numbers behind argenx's P/E valuation .

The argenx Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for argenx pick up where the P/E debate leaves off by spelling out which paths for argenx's growth, margins and earnings would need to occur for the share price to look meaningfully higher or lower than today. They sit on the Community page so you can see that story evolve over time. Instead of a single output from a ratio or model, Narratives lay out the future that number quietly assumes so you can track whether reality lines up with it.